Denosumab--a novel strategy to prevent structural joint damage in patients with RA?

Affiliations

Comment

Georg Schett et al. Nat Clin Pract Rheumatol. 2008 Dec.

. 2008 Dec;4(12):634-5.

doi: 10.1038/ncprheum0927. Epub 2008 Oct 7.

¹ Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen 91054, Germany. georg.schett@uk-erlangen.de

No abstract available

Comment on

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R; Denosumab Rheumatoid Arthritis Study Group. Cohen SB, et al. Arthritis Rheum. 2008 May;58(5):1299-309. doi: 10.1002/art.23417. Arthritis Rheum. 2008. PMID: 18438830 Clinical Trial.